Immedica
Immedica at a glance
Immedica is engaged in the launch, commercialisation and distribution of orphan and niche specialty pharmaceuticals across Europe and the Middle East. The company is built on the initial acquisition of Medical Need Europe followed by the recruitment of a new management team and over 10 add-on investments. Currently, Immedica distributes a portfolio of c. 25 drugs, spanning proprietary, in-licensed and partnered products with a focus on genetic and metabolic diseases, oncology, and ophthalmology. Immedica is quickly scaling across Europe with a vision to become the leading player in launching niche specialty pharmaceuticals targeting diseases with high unmet medical needs.
Immedica facts
Pharmaceuticals
May 2018
Stockholm, Sweden
Anders Edvell (CEO)
Simon Falk (CFO)
Magnus Edlund
Fredrik Odin
Edvard Hubendick
100
Investment thesis
- Launch and commercialisation of rare disease drugs in the EU and ME is a highly attractive and sustainable business
- Potential to expand into a leading pan-European position in a market with high barriers to entry
- Clear opportunity to multiply size by pursuing an active business development agenda, spanning distribution, in-licensing deals and acquisitions
UN SDG Goals
Other portfolio companies
Avia Pharma
Avia is a leading North European OTC/Rx platform
Stille
Stille is a well-established pioneer in the development of premium surgical instruments and advanced surgical tables
Decon
Decon develops, assembles, and distributes high-quality, power-assisted electrical solutions for wheelchairs